In our study, we are the first to demonstrate in glioma cells that YTHDF2 binds to m6A -modified APC and GSK3β mRNA, promoting their degradation and thereby activating the Wnt-β-Catenin pathway. The gene discussed is YTHDF2; the disease is central nervous system cancer.